title: Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
authors.forename: Edward E
authors.initials: EE
authors.lastname: Winger
authors.forename: Jane L
authors.initials: JL
authors.lastname: Reed
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000013:Congenital Abnormalities / Q000453:epidemiology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha